［1］Ferlay J，Shin HR，Bray F，et al.Estimates of worldwide burden of cancer in 2008：GLOBOCAN 2008［J］.Int J Cancer，2010，127(12)：2893-2917.
［2］Shitara K，Ikeda J，Kondo C，et al.Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer［J］.Gastric Cancer，2012，15(2)：137-143.
［3］Yoo CH，Noh SH，Shin DW，et al.Recurrence following curative resection for gastric carcinoma［J］.Br J Surg，2000，87(2)：236-242.
［4］Shin A，Kim J，Park S.Gastric cancer epidemiology in Korea［J］.J Gastric Cancer，2011，11(3)：135-140.
［5］Schlansky B，Sonnenberg A.Epidemiology of noncardia gastric adenocarcinoma in the United States［J］.Am J Gastroenterol，2011，106(11)：1978-1985.
［6］Yu XQ，Zheng ZC.Progress in the treatment of gastric cancer metastasis［J］.Modern Oncology，2013，21(10)：2373-2375.［于先强，郑志超.胃癌肝转移治疗研究进展［J］.现代肿瘤医学，2013，21(10)：2373-2375.］
［7］He YL.Surgical treatment of gastric cancer hepatic metastasis［J］.Chin J Gastrointestinal Surg，2014，17(2)：105-107.［何裕隆.胃癌肝转移的外科治疗［J］.中华胃肠外科杂志，2014，17(2)：105-107.］
［8］Shimada H，Noie T，Ohashi M，et al.Clinical significance of serum tumor markers for gastric cancer：a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association［J］.Gastric Cancer，2014，17(1)：26-33.
［9］Zhou M，Wang C，Hu S，et al.18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer：a comparison with 18F-FDG PET/CT imaging［J］.Nucl Med Commun，2013，34(7)：694-700.
［10］Wang D，Zhang GB，Yan L，et al.CT and enhanced CT in diagnosis of gastrointestinal neuroendocrine carcinomas［J］.Abdom Imaging，2012，37(5)：738-745.
［11］Ozkan E，Araz M，Soydal C，et al.The role of 18F-FDG-PET/CT in the preoperative staging and posttherapy follow up of gastric cancer：comparison with spiral CT［J］.World J Surg Oncol，2011，9：75.
［12］Marrelli D，Roviello F，De Stefano A，et al.Risk factors for liver metastases after curative surgical procedures for gastric cancer：a prospective study of 208 patients treated with surgical resection［J］.J Am Coll Surg，2004，198(1)：51-58.
［13］Liu J，Chen L.Current status and progress in gastric cancer with liver metastasis［J］.Chin Med J (Engl)，2011，124(3)：445-456.
［14］Jerraya H，Saidani A，Khalfallah M，et al.Management of liver metastases from gastric carcinoma：where is the evidence［J］？ Tunis Med，2013，91(1)：1-5.
［15］Okano K，Maeba T，Ishimura K，et al.Hepatic resection for metastatic tumors from gastric cancer［J］.Ann Surg，2002，235(1)：86-91.
［16］Schildberg CW，Croner R，Merkel S，et al.Outcome of operative therapy of hepatic metastatic stomach carcinoma：a retrospective analysis［J］.World J Surg，2012，36(4)：872-878.
［17］Yang SW，Kim MG，Lee JH，et al.Role of metastasectomy on overall survival of patients with metastatic gastric cancer［J］.J Gastric Cancer，2013，13(4)：226-231.
［18］Takemura N，Saiura A，Koga R，et al.Long-term outcomes after surgical resection for gastric cancer liver metastasis：an analysis of 64 macroscopically complete resections［J］.Langenbecks Arch Surg，2012，397(6)：951-957.
［19］Gadde R，Tamariz L，Hanna M，et al.Metastatic gastric cancer (MGC) patients：Can we improve survival by metastasectomy? A systematic review and Meta-analysis［J］.J Surg Oncol，2015，112(1)：38-45.
［20］Sakamoto Y，Sano T，Shimada K，et al.Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer［J］.J Surg Oncol，2007，95(7)：534-539.
［21］Roh HR，Suh KS，Lee HJ，et al.Outcome of hepatic resection for metastatic gastric cancer［J］.Am Surg，2005，71(2)：95-99.
［22］Kanda T，Yajima K，Kosugi S，et al.Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy：a multi-institute retrospective study［J］.Gastric Cancer，2012，15(3)：235-244.
［23］Polysalov VN，Veriasova NN，Dolgikh SD，et al.Regional chemotherapy in locally advanced and metastatic gastric cancer［J］.Vopr Onkol，2012，58(6)：762-767.
［24］Choda Y，Ninomiya M，Kanazawa T，et al.Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve R0 resection after capecitabine，cisplatin，and trastuzumab chemotherapy-a case report［J］.Gan To Kagaku Ryoho，2014，41(11)：1421-1424.
［25］Li Z，Fan B，Shan F，et al.Gastrectomy in comprehensive treatment of advanced gastric cancer with synchronous liver metastasis：a prospectively comparative study［J］.World J Surg Oncol，2015，13：212.
［26］Tsujimoto H，Ichikura T，Ono S，et al.Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer［J］.Hepatol Int，2010，4(1)：406-413.
［27］Orditura M，Galizia G，Sforza V，et al.Treatment of gastric cancer［J］.World J Gastroenterol，2014，20(7)：1635-1649.
［28］Chen L，Song MQ，Lin HZ，et al.Chemotherapy and resection for gastric cancer with synchronous liver metastases［J］.World J Gastroenterol，2013，19(13)：2097-2103.
［29］Qiu JL，Deng MG，Li W，et al.Hepatic resection for synchronous hepatic metastasis from gastric cancer［J］.Eur J Surg Oncol，2013，39(7)：694-700.
［30］Van Cutsem E，Moiseyenko VM，Tjulandin S，et al.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer：a Report of the V325 Study Group［J］.J Clin Oncol，2006，24(31)：4991-4997.
［31］Bang YJ，Van Cutsem E，Feyereislova A，et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)：a phase 3，open-label，randomised controlled trial［J］.Lancet，2010，376(9742)：687-697.
［32］Li ZY，Shan F，Zhang LH，et al.Preoperative chemotherapy with a trastuzumab-containing regimen for a patient with gastric cancer and hepatic metastases［J］.Genet Mol Res，2014，13(4)：10952-10957.
［33］Fisher SB，Fisher KE，Squires MH，et al.HER2 in resected gastric cancer：Is there prognostic value［J］？ J Surg Oncol，2014，109(2)：61-66.
［34］Aizawa M，Nagatsuma AK，Kitada K，et al.Evaluation of HER2-based biology in 1 006 cases of gastric cancer in a Japanese population［J］.Gastric Cancer，2014，17(1)：34-42.
［35］Su D，Bai L.Liver metastasis of gastric cancer chemotherapy and targeted therapy［J］.Chin J Gastrointestinal Surg，2014，17（2）：112-116.［苏丹，白莉.胃癌肝转移的化疗和靶向治疗［J］.中华胃肠外科杂志，2014，17(2)：112-116.］
［36］Van Cutsem E，de Haas S，Kang YK，et al.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer：a biomarker evaluation from the AVAGAST randomized phase III trial［J］.J Clin Oncol，2012，30(17)：2119-2127.
［37］Ohtsu A，Shah MA，Van Cutsem E，et al.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer：a randomized，double-blind，placebo-controlled phase III study［J］.J Clin Oncol，2011，29(30)：3968-3976.
［38］Chen L，Lu CR.Evaluation of multidisciplinary treatment of gastric cancer metastasis［J］.Chin J Bases and Clinics，2012，19(1)：4-7.［陈凛，卢灿荣.胃癌肝转移多学科治疗评价［J］.中国普外基础与临床杂志，2012，19(1)：4-7.］
［39］Hwang JE，Kim SH，Jin J，et al.Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer［J］.Clin Exp Metastasis，2014，31(1)：25-32.
［40］Fukuda Y，Takeshima F，Ogihara K，et al.Successful management of liver metastasis from gastric adenosquamous carcinoma with adjuvant chemotherapy and radiofrequency ablation［J］.Nihon Shokakibyo Gakkai Zasshi，2012，109(4)：606-614.
［41］Kim HR，Cheon SH，Lee KH，et al.Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma［J］.Int J Hyperthermia，2010，26(4)：305-315.
［42］Matsuno H，Hirao M，Tanaka E，et al.A long-term survival case of liver metastases from gastric cancer treated with radiofrequency ablation and radiotherapy［J］.Gan To Kagaku Ryoho，2011，38(12)：1957-1959.
［43］Kimura Y，Taniguchi H，Yano H，et al.A case of liver metastasis from gastric cancer treated with stereotactic radiation therapy［J］.Gan To Kagaku Ryoho，2010，37(12)：2499-2501.
［44］Katayanagi S，Shimazu M，Konno O，et al.A case of liver metastases from gastric cancer treated with stereotactic body radiation therapy［J］.Gan To Kagaku Ryoho，2011，38(12)：2097-2099.
［45］Hasuike Y，Iwagami Y，Toyomasu T，et al.Efficacy of combined local therapy especially with hepatic arterial infusion for liver metastasis from gastric cancer［J］.Gan To Kagaku Ryoho，2013，40(12)：1644-1646.
［46］Whitney R，Tatum C，Hahl M，et al.Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy［J］.J Surg Res，2011，166（2)：236-240.